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Abstract
Tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR-TKIs) are standard treatments for advanced
non-small-cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR)
mutations. Nowadays, tumor tissues acquired by surgery or biopsy are the routine materials for EGFR mutation
analysis. However, the accessibility of tumor tissues is not always satisfactory in advanced NSCLC. Moreover, a high
proportion of NSCLC patients will eventually develop resistance to EGFR-TKIs. Invasive procedures, such as surgery
or biopsy, are impractical to be performed repeatedly to assess the evolution of EGFR-TKI resistance. Thus, exploring
some convenient and less invasive techniques to monitor EGFR-TKI treatment is urgently needed. Circulating
cell-free tumor DNA (ctDNA) has a high degree of specificity to detect EGFR mutations in NSCLC. Besides, ctDNA is
capable of monitoring the disease progression during EGFR-TKI treatment. Certain serum microRNAs that correlate
with EGFR signaling pathway, such as miR-21 and miR-10b, have been demonstrated to be helpful in evaluating
the efficiency of EGFR-TKI therapeutics. A commercialized serum-based proteomic test, named VeriStrat test, has
shown an outstanding ability to predict the clinical outcome of NSCLC patients receiving EGFR-TKIs. Analysis of
EGFR mutations in circulating tumor cells (CTCs) is feasible, and CTCs represent a promising material to predict
EGFR-TKI-treatment efficacy and resistance. These evidences suggested that non-invasive techniques based on serum
or plasma samples had a great potential for monitoring EGFR-TKI treatment in NSCLC. In this review, we summarized
these non-invasive approaches and considered their possible applications in EGFR-TKI-treatment monitoring.
Keywords: Epidermal growth factor receptor, Tyrosine kinase inhibitors, Circulating cell-free tumor DNA, MicroRNAs,
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Introduction
Lung cancer is the most commonly diagnosed cancer as well
as the leading cause of cancer-related deaths [1]. Non-small-
cell lung cancer (NSCLC) accounts for approximately 83 %
of all lung cancers, and nearly 80 % of NSCLC patients are
diagnosed with advanced or distant stages [2]. So far, the
common cancer-driver genes identified in NSCLC include
the mutant activations of Kirsten rat sarcoma (KRAS), epi-
dermal growth factor receptor (EGFR), proto-oncogene
B-Raf (BRAF), and phosphoinositide-3-kinase, catalytic, α
polypeptide gene (PIK3CA) [3]. Several other molecular al-
terations, such as echinoderm microtubule-associated
protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fu-
sion [4], Notch signaling activation [5, 6], and dysregulation
of the nucleo-cytoplasmic transport of proteins [7], also par-
ticipate in NSCLC progression. Multiple small-molecule in-
hibitors directed at these molecular targets have been
extensively developed, and some of them are migrating
from bench to bedside [4, 7, 8]. However, despite these
rapid progresses, tyrosine kinase inhibitors of epidermal
growth factor receptor (EGFR-TKIs) are still the most suc-
cessful example of targeted therapy in NSCLC. Compared
with conventional chemotherapy, EGFR-TKIs can achieve
prolonged progression-free survival (PFS) with reduced
side effects in NSCLC patients harboring activating EGFR
mutation [9].
Nowadays, EGFR gene mutations are the standard pre-
dictive biomarkers for selecting NSCLC patients to receive
EGFR-TKI treatment. The point mutation in exon 21
(L858R) or deletion in exon 19 predicts good response to
EGFR-TKIs [10], while the point mutation (T790M) in
exon 20 implies resistance to EGFR-TKIs [11]. The
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routine materials for EGFR mutation analyses are tumor
tissues acquired by surgery or biopsy. However, assess-
ment of EGFR mutation status depending on tumor tis-
sues has many limitations. First, the accessibility of tumor
tissues is not always satisfactory. Most NSCLC patients
are diagnosed with advanced or distant stages. Performing
surgery or biopsy to obtain tissues from these patients is
often impractical. Only 20 % to 50 % NSCLC patients
could provide sufficient tissues to receive molecular ana-
lysis even in large well-designed clinical trials [9, 12–15].
Second, a high proportion of NSCLC patients will eventu-
ally develop EGFR-TKI resistance [16, 17]. Identifying a
molecular mechanism of acquired resistance to EGFR-
TKIs and developing relevant targeted drugs are needed
for effective second-line treatments [18, 19]. But, assessing
treatment resistance in real time by tumor tissues is not
feasible as repeated surgery or biopsy is inappropriate in
most patients. Furthermore, surgery and biopsy are not
without clinical complications. The adverse event rates for
thoracic biopsies were reported to be 17.1 % [20]. Consid-
ering these limitations, exploring some convenient, eco-
nomic, and less invasive techniques to monitor EGFR-TKI
treatment in NSCLC is urgently needed.
Non-invasive approaches, usually based on plasma or
serum samples, showed great potential for monitoring
EGFR-TKI treatment in recent years. Circulating cell-free
tumor DNA (ctDNA), which is released from tumor cells
to circulating blood, can be applied to detect EGFR muta-
tions in NSCLC patients [21–23]. Moreover, the dynamic
changes in ctDNA EGFR mutation status could predict the
clinical outcome of EGFR-TKI treatment [24]. MicroRNAs
(miRNAs) are associated with tumor progression, suggest-
ing their potential applications for treatment monitoring.
Several serum miRNAs have been identified to associate
with response to EGFR-TKIs in NSCLC [25, 26]. Circulat-
ing miRNAs may also act as potential non-invasive bio-
markers to monitor EGFR-TKI treatment. Serum
proteomics is an emerging science. Analyzing serum for
specific proteins by mass spectrometry is becoming an im-
portant tool to identify biomarkers in cancers [27]. The
VeriStrat test, a commercialized serum-based proteomic
test, has emerged as a promising approach to predict the
outcome of NSCLC patients receiving EGFR-TKIs [28–31].
Circulating tumor cells (CTCs) can be detected in the
blood of many cancer patients and play an important role
in metastasis. Several studies have demonstrated that EGFR
mutation status in CTCs matches well with that in tumor
tissues [32–34]. Isolating DNA from CTCs to receive EGFR
mutation analysis may be another effective way to monitor
EGFR-TKI treatment.
In summary, serum ctDNA, miRNAs, proteomic bio-
markers, and CTCs can be obtained non-invasively, mak-
ing them ideal substitutes for tumor tissues (Fig. 1). In
addition, these liquid biopsies can be performed multiple
times and allow for dynamic detection of molecular
changes in tumor cells. Hereby, we summarized these non-
invasive approaches in this review and considered their
possible applications in monitoring EGFR-TKI treatment.
Circulating cell-free tumor DNA (ctDNA)
Cancer-associated genetic alterations, such as point muta-
tions, deletions, copy number variations, and methylation
patterns, can be detected in ctDNA [35, 36]. In NSCLC,
ctDNA shows a high diagnostic accuracy for EGFR muta-
tion analyses. Moreover, serum ctDNA analysis could
effectively predict the efficacy of EGFR-TKI treatment and
identify the molecular changes associated with EGFR-TKI
resistance.
Detection of EGFR gene mutations
When ctDNA is used to analyze gene mutations in
NSCLC patients, one vital issue is whether the genetic
variation within blood was consistent with tumor tissues.
Table 1 summarizes studies which detected EGFR muta-
tions in NSCLC patients using ctDNA. As shown, a wide
range of diagnostic accuracy values were reported. The
sensitivities for ctDNA ranged from 17.1 % [23] to
100 % [37, 38], while the specificities were from 71.4 %
[39] to 100 % [23, 37, 40–47]. Additionally, the concord-
ance rates between ctDNA and tumor tissues showed a
big variation, ranging from 27.5 % [23] to 100 % [37].
The large variability among various studies might be
caused by different laboratory procedures and tech-
niques utilized for quantification of ctDNA. Besides,
the big difference in the numbers of patients might also
influence the reported sensitivity and specificity. To ad-
dress these issues, two recent meta-analyses were per-
formed [48, 49]. Their main purposes were to compare
ctDNA with tumor tissues in terms of its diagnostic ac-
curacy for the detection of EGFR mutations. Both of
their results revealed that ctDNA had high diagnostic
accuracy for the detection of EGFR mutations in
NSCLC. The pooled sensitivities for ctDNA in these two
meta-analyses were reported to be 67.4 % and 62 %,
respectively. And the specificities for ctDNA were 93.5 %
and 95.9 %, respectively. These evidences suggested that
assessment of EGFR mutations by ctDNA has adequate
diagnostic accuracy, especially the high degree of specifi-
city. Thus, ctDNA is a highly specific and effective bio-
marker for EGFR mutation analyses. Future standard
techniques for detecting EGFR mutations in ctDNA might
validate its clinical value in NSCLC patients.
Prediction of EGFR-TKI-treatment efficacy
Regarding the clinical application of ctDNA, another im-
portant issue is whether ctDNA is capable of predicting
EGFR-TKI-treatment efficacy. Indeed, several studies have
analyzed the association between pre-treatment ctDNA
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EGFR mutation status and clinical outcomes. Goto et al.
[40] evaluated EGFR mutations in ctDNA from patients in
the IPASS study recruited in Japan (IPASS, The IRESSA
Pan-Asia Study). A significant correlation between ctDNA
EGFR mutation status and PFS was founded in this study.
PFS was significantly longer with gefitinib than carbopla-
tin/paclitaxel in the activating ctDNA EGFR mutation
subgroup (hazard ratio (HR), 0.29; 95 % confidence inter-
val (CI), 0.14–0.60). Another large-scale research also
demonstrated that EGFR mutation status in ctDNA was a
good predictor for PFS after EGFR-TKI therapy (mutant
versus wild-type: 10.1 versus 3.7 months, p = 0.038) [50].
Recently, the predictive value of the dynamic changes in
ctDNA EGFR mutation status during therapy was ex-
plored by a prospective study [24]. In this study, patients
were randomized to receive six cycles of gemcitabine/plat-
inum plus sequential erlotinib or placebo. Blood samples
at baseline, cycle 3, and progression were assessed. In pa-
tients with ctDNA-based EGFR mutation-positive status
at baseline, those that transformed to EGFR mutation-
negative status had better PFS and overall survival (OS)
than those with detectable EGFR mutations at cycle 3.
These data suggested that dynamic changes of EGFR
status in ctDNA were able to predict the benefit of EGFR-
TKI treatment. In conclusion, ctDNA EGFR mutation test
has a good ability to predict EGFR-TKI-treatment efficacy,
Fig. 1 Clinical applications of non-invasive approaches in monitoring EGFR-TKI treatment for NSCLC patients. This schematic diagram depicts the
applications of common non-invasive approaches in monitoring EGFR-TKI treatment for NSCLC. Before therapy, ctDNA, CTCs, miRNAs, and
proteomic tests help to identify appropriate NSCLC patients to receive EGFR-TKIs. During the course of treatment, ctDNA, CTCs, and miRNAs can
be used to monitor EGFR-TKI-treatment response and track EGFR-TKI-treatment resistance. At the time of disease progression, ctDNA, CTCs, and
miRNAs reveal the molecular changes related to EGFR-TKI resistance
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and it may be a reliable approach to guide EGFR-TKI
treatments for NSCLC patients.
Tracking molecular changes related to EGFR-TKI
resistance
In NSCLC, despite an initial response, resistance to
EGFR-TKIs will occur and thereafter tumor progresses.
For this reason, identification of the molecular mecha-
nisms of EGFR-TKI resistance is needed. Several mecha-
nisms responsible for EGFR-TKI acquired resistance have
been described, including the second T790M mutation of
EGFR, amplification of MET or HER2, and mutations of
PIK3CA or BRAF [51, 52]. The second T790M mutation
of EGFR accounts for half of the TKI-resistant cases, and
monitoring T790M mutation is useful for the estimate of
EGFR-TKI resistance. Taniguchi et al. performed a study
to quantitatively detect the T790M-resistant mutations in
ctDNA [53]. In 43.5 % (10/23) of patients who had pro-
gressive disease after EGFR-TKI treatment, the T790M
mutation in ctDNA was detected. Another study also
proved that sequencing of plasma DNA could comple-
ment current invasive approaches to identify mutations
associated with acquired drug resistance in advanced can-
cers [36]. This study tracked the genomic evolution during
therapy in various kinds of cancer patients by the sequen-
cing of cancer exomes in serial plasma samples. It revealed
that the EGFR T790M mutation in plasma could be
detected at progression, but not at the start of treatment
Table 1 EGFR mutations detected in ctDNA of NSCLC patients
Authors Case number Method Positive (%) Sensitivity (%) Specificity (%) Concordance (%)
Sun H [21] 55 MST-PCR 18.2 NM NM NM
Douillard JY [22] 784 ARMS 10.5 65.7 99.8 94.3
Kim HR [23] 40 PNA-PCR 15 17.1 100 27.5
Punnoose EA [37] 24 DxS kits 16.7 100 100 100
Goto K [40] 194 DxS Kits + ARMS 23.7 43 100 66.3
Jian G [81] 56 RT-PCR 23.2 NM NM NM
He C [38] 134 ME-PCR 49.3 100 90 94.4
Zhang L [82] 627 ME-PCR 22 NM NM NM
Zhao X [83] 111 ME-PCR + sequencing 17.1 35.6 95.5 71.2
Kimura H [39] 27 PCR + sequencing 37 75 71.4 NM
Kim ST [84] 57 PNA-LNA PCR 19.3 66.7 93.3 87.7
Bai H [85] 230 DHPLC 34.3 81.8 89.5 74
Yung TK [41] 35 Digital PCR 43 92 100 NM
Mack PC [42] 49 DxS kits 20.4 66.7 100 NM
Kuang Y [86] 54 ARMS 47 70 85 NM
Kimura H [87] 42 ARMS 16.7 75 97.1 92.9
Kimura H [88] 27 ARMS 48.1 50 85.7 72.7
Brevet M [89] 31 ME-PCR + sequencing 58.1 38.9 84.6 NM
Jiang B [43] 58 ME-PCR + sequencing 24.1 77.8 100 93.1
Wang S [90] 134 ARMS 12.7 22.1 97 59
Jing CW [91] 120 HRM 25.8 64.4 97.3 85
Zhang H [44] 86 MEL 17.4 68.2 100 91.9
Liu X [45] 86 ARMS 31.4 67.5 100 84.9
Xu F [46] 34 ARMS 11.8 50 100 88.2
Huang Z [92] 822 DHPLC 32.7 63.5 84.6 77
Sriram KB [47] 64 ME-PCR 4.7 50 100 95.3
Weber B [50] 196 cobas® EGFR test 11.7 60.7 96.4 91.3
MST mutant-specific primers with a Taqman probe, PCR polymerase chain reaction, ARMS the amplification refractory mutation system, PNA-PCR peptide
nucleic-acid-mediated PCR, DxS kits DxS EGFR Mutation Test Kit (DxS, Manchester, UK), RT-PCR real-time PCR, ME-PCR mutant-enriched PCR, PNA-LNA PCR the
peptide nucleic-acid-locked nucleic acid PCR, DHPLC denaturing high-performance liquid chromatography, HRM high-resolution melting analysis, MEL
mutant-enriched liquidchip, NM not mentioned
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in NSCLC patients treated with gefitinib. These results
suggested that ctDNA was capable of monitoring disease
progression during EGFR-TKI therapy.
MicroRNAs
MicroRNAs (miRNAs) play critical roles in tumor develop-
ment, including tumor initiation, invasion, and metastasis
[54–56]. Several miRNAs that correlate with the EGFR sig-
naling pathway have been demonstrated to mediate EGFR-
TKI resistance in NSCLC [57–60]. Moreover, circulating
miRNAs are emerging as promising biomarkers and thera-
peutic targets for many cancers [61–65]. Many studies have
shown that changes in circulating miRNAs during treat-
ment are predictive of tumor response [63, 66, 67]. Circu-
lating microRNAs may have the potential to be developed
into next-generation biomarkers for cancer screening. In
NSCLC patients, certain miRNAs have been detected in
the serum samples. These circulating miRNAs are showing
their potential in EGFR-TKI-treatment monitoring [25, 26].
Shen et al. performed a study to identify the miRNA
panel in the serum of NSCLC patients with different EGFR
mutation status [26]. They revealed that the expressions of
serum miR-21 and miR-10b were much higher in patients
with EGFR mutation than those without mutation. In
addition, patients with up-regulated miR-21 expression had
a shorter OS time, suggesting that miR-21 expression may
be a reliable predictor for gefitinib-treatment efficacy. Fur-
thermore, the levels of miR-10b expression in progressive
patients were significantly higher than those in non-
metastatic patients. These results suggested that the expres-
sion of circulating miRNAs differed between patients with
positive and negative EGFR mutation status and the levels
of circulating miRNAs are associated with response to
EGFR-TKI therapy.
Another study, which aimed to investigate the role of
miR-21 in the acquired resistance to EGFR-TKIs, showed
that miR-21 can mediate EGFR-TKI resistance by down-
regulating PTEN and PDCD4 and activating the PI3K/Akt
pathway [25]. Besides, it revealed that the serum miR-21
expression in NSCLC patients receiving EGFR-TKIs was
much higher at the time of acquired resistance than that at
baseline. These evidences indicated that circulating miR-21
might act as an available biomarker to monitor the acquired
resistance to EGFR-TKIs.
The above available evidences suggested that serum miR-
21 and miR-10b were helpful for monitoring EGFR-TKI
treatment. Future data may update these results and valid-
ate the practical utility of circulating miRNAs in NSCLC.
Proteomic biomarkers
Similar to other high-throughput technologies, proteomics
are able to detect multiple proteins that are expressed as a
cause or consequence of ongoing diseases [68]. Proteomic
profiles of various specimens obtained from cancer patients
are expected to increase our understanding of tumor
pathogenesis and cancer therapy. In the management of
NSCLC, proteomic profiles have been shown to be useful
in disease detection, diagnosis, treatment, and prognostica-
tion [69]. Recent studies revealed that a simple serum-
based proteomic test had a great potential for selecting
NSCLC patients to receive EGFR-TKI treatment [28–31].
Taguchi and his colleagues reported a mass spectrometry
serum test which was able to identify a subset of NSCLC
patients with better outcomes after EGFR-TKI therapy in
2007 [28]. Then this test was commercialized under the
name of VeriStrat and applied in multiple clinical trials.
This novel test used the integrated intensities of eight mass
spectral peaks and classified patients into VeriStrat “good”
and VeriStrat “poor” statuses. Several subsequent studies
also demonstrated that VeriStrat “good” patients could
benefit more from EGFR-TKI therapy than “poor” ones
[29–31, 70, 71]. Additionally, a large meta-analysis based
on these studies confirmed that the VeriStrat “good” status
predicted a better clinical outcome with a pooled HR of
0.40 (95 % CI, 0.32 to 0.49; p = 0.000) for OS and 0.49
(95 % CI, 0.39 to 0.60; p = 0.000) for PFS [72]. Furthermore,
the original study has tested the concordance of mass spec-
trometry generated by two independent institutions [28].
Their results indicated that the VeriStrat test had an out-
standing reproducibility. Thus, the VeriStrat test might be a
potential tool to predict the clinical outcome of NSCLC
patients after treatment with EGFR-TKIs.
The PROSE trial, the first prospective, randomized prote-
omic stratified phase III study, was designed to evaluate the
predictive value of the VeriStrat test on the outcome in
advanced NSCLC patients treated with either EGFR-TKIs
or standard chemotherapy [73]. Information provided by
this trial suggested that this proteomic test is predictive of
OS benefit for erlotinib and chemotherapy. Patients with a
VeriStrat “poor” status had worse survival on erlotinib than
on chemotherapy (HR, 1.72; 95 % CI, 1.08–2.74; p = 0.022).
Chemotherapy is likely to result in improved outcomes for
patients with a VeriStrat “poor” status. This trial comple-
mented the results of previous retrospective studies and
helped to identify the subgroup of NSCLC patients who
may not benefit from EGFR-TKIs.
In this emerging field, the number of studies is relatively
limited but growing. Another phase III study (EMPHASIS)
was opened for advanced squamous cell NSCLC (Clinical-
trials.gov identifier: NCT01652469). Patients with relapsed
squamous cell lung cancer are assigned to two groups
(VeriStrat “good” and VeriStrat “poor”) and then random-
ized between EGFR-TKI (erlotinib) and chemotherapy
(docetaxel). One of its goals is to explore the predictive and
prognostic ability of the VeriStrat test signature. In addition,
a clinical trial that aims to measure whether VeriStrat could
be a biomarker of benefit from treatment with standard
chemotherapy regimens in first-line NSCLC patients is
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currently recruiting participants (Clinicaltrials.gov identifier:
NCT02055144). These ongoing trials may prospectively
validate the predictive role of this serum-based proteomic
test in NSCLC patients.
Circulating tumor cells
Circulating tumor cells (CTCs), which are disseminated
from tumor tissues, have the potential to complement
tumor tissues for tumor characterization and cancer-
treatment monitoring [74]. Various kinds of genetic abnor-
malities, such as KRAS mutation [75], EGFR mutation [32,
33], and ALK rearrangement [76–78], have been identified
in CTCs from NSCLC patients. Moreover, CTCs represent
promising materials for EGFR-TKI-treatment monitoring.
Detection of EGFR gene mutations
The EGFR gene mutation profiles of CTCs in NSCLC have
been analyzed by several studies. Recently, a study investi-
gated the EGFR mutations in CTCs by coupling the Cell-
Search System with next-generation sequencing (NGS)
[32]. In 37 advanced NSCLC patients harboring activating
EGFR mutations in tumor tissues, 31 cases were identified
to have the EGFR mutations in CTCs. Additionally, 94 %
(29/31) of the mutation types detected by NGS on CTCs
were in accordance with that found in matched tumor tis-
sues. These data suggested that CTCs represented a suit-
able source for detection of EGFR mutations. Another
study developed an available method to detect EGFR muta-
tions in single CTC [33]. The laser cell microdissection
(LCM) technique was used to isolate individual CTCs.
Then it was followed by the whole-genome amplification of
DNA for exon 19 deletion and L858R and T790M muta-
tion detection. Ninety-five percent (19/20) of the single
CTC underwent PCR amplicons for at least one of the
three mutation sites. The amplification success rates were
55 % (11/20) for exon 19 deletion, 45 % (9/20) for T790M,
and 85 % (17/20) for L858R. These results suggested that
detecting EGFR mutations in CTCs was feasible. CTCs
may be available materials for the detection of EGFR muta-
tions in NSCLC.
Monitoring EGFR-TKI-treatment efficacy
As mentioned above, the dynamic changes in ctDNA-based
EGFR status are able to predict the benefit of EGFR-TKI
treatment [24]. Similarly, EGFR mutation status in CTCs
can be another biomarker for monitoring EGFR-TKI-
treatment efficacy. Breitenbuecher et al. adopted an assay
based on real-time polymerase chain reaction and melting
curve analysis to detect activating EGFR mutations in CTCs
[34]. All CTCs in baseline blood samples from eight
NSCLC patients were found to harbor the EGFR mutations
that corresponded with tumor tissues. During treatment,
sequential samples from four of eight patients turned
“negative” for EGFR mutations. These four patients who
“cleared” EGFR-mutant CTCs achieved disease control,
with three partial responses (PRs) and one stable disease
(SD). In the remaining four patients with persisting EGFR-
mutant CTCs, only one had PR. In addition, patients who
had “cleared” EGFR-mutant CTCs showed a significantly
longer recurrence-free time when compared with patients
whose EGFR mutations in CTCs remained “positive” (me-
dian time, 355 versus 116 days). With the follow-up time
extending, all four patients with “cleared” EGFR-mutant
CTCs developed progressive disease. Interestingly, EGFR
mutation status in CTCs from these four patients returned
to “positive” prior to clinical progression. Thus, an increase
in EGFR-mutant CTC counts might be an early indicator
for disease relapse and EGFR-TKI resistance. Moreover,
changes in CTC levels were also capable of predicting the
outcome of EGFR-TKI treatment. Punnoose et al. per-
formed a study to evaluate the utility of CTCs in NSCLC
patients treated with pertuzumab and erlotinib [37]. Their
results revealed that decreased CTC counts upon treatment
were associated with better response and longer PFS. Thus,
Table 2 Summary of non-invasive approaches to monitor EGFR-TKI treatment in NSCLC patients
Non-invasive
approaches
Methods Sensitivity Specificity Advantages Disadvantages Cost
ctDNA PCR-based techniques;
DNA sequencing
Moderate High Feasible on small-amount samples;
suitable for detecting specific genes;
high reproducibility
Normalization problems Low
MicroRNAs RT-PCR-based techniques Moderate High Feasible on small-amount samples;







Mass spectrometry High Moderate Feasible on small-amount samples;





CTCs Cell enrichment techniques
+ PCR-based techniques or
DNA sequencing







ctDNA circulating cell-free tumor DNA, PCR polymerase chain reaction, RT-PCR reverse transcription-polymerase chain reaction, CTCs circulating tumor cells
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CTCs are effective to monitor EGFR-TKI-treatment effi-
cacy in NSCLC patients.
Tracking emergence of EGFR-TKI resistance
DNA extracted from CTCs, like other sources of DNA, has
been shown to be an effective material for the detection of
the T790M mutation of EGFR in NSCLC. Maheswaran et
al. performed an EGFR mutation analysis on CTCs in
NSCLC patients treated with EGFR-TKIs [79]. T790M
mutation was detected in CTCs from 9 of 14 patients
(64 %) who had clinical progression. This finding was
consistent with the reported prevalence of T790M
(about 50 %) [80]. Hence, CTCs collected during treat-
ment might provide a potential alternative for EGFR-
TKI-resistance analysis. Future large-scaled prospect-
ive studies may verify the practical utility of CTCs in
EGFR-TKI-treatment monitoring.
Conclusions
Non-invasive approaches, usually based on serum or
plasma samples, are showing great potential to monitor
EGFR-TKI treatment in NSCLC (Fig. 1 and Table 2).
ctDNA has a high degree of specificity to detect EGFR
mutations. Moreover, ctDNA is capable of monitoring dis-
ease progression during EGFR-TKI treatment. Certain
serum microRNAs, such as miR-21 and miR-10b, can ef-
fectively predict the EGFR-TKI-treatment efficacy and
resistance. The VeriStrat test has been proved to be help-
ful for selecting NSCLC patients to receive EGFR-TKIs.
CTCs are feasible for EGFR mutation analysis and repre-
sent promising materials to monitor EGFR-TKI treatment.
Thus, these liquid specimens can complement with tumor
tissues and help to guide EGFR-TKI therapy in NSCLC.
As numerous high-throughput detection techniques are
being developed extensively, liquid samples obtained by
non-invasive approaches possess great potential to be
valuable materials applied for guiding individual treat-
ment. However, several hurdles should be overcome be-
fore applying these approaches into routine clinical
practice (Table 2). One of the most important issues is the
lack of consensus in technical approaches. Future stand-
ard and universal techniques for these non-invasive ap-
proaches may validate their applications in monitoring
EGFR-TKI treatment in NSCLC.
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